Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA IV: You Can't Always Get What You Want

This article was originally published in RPM Report

Executive Summary

Former Senate HELP Committee FDA counsel Steven Irizarry looks ahead at the reauthorization of PDUFA and what drug companies should expect in the latest round of negotiations.

You may also be interested in...



FDA in a Shutdown: The Plan Still Matters

A government shutdown was averted but not until federal agency’s were forced to communicate their shutdown plans to employees and the public. Those plans may have a lingering impact—and not just because the threat of a shutdown is sure to arise again.

Omnitrope Clears FDA: Is the Next Hurdle Congress?

The debate over an abbreviated biologics pathway took a big step forward with the Food & Drug Administration's approval of Sandoz' recombinant human growth hormone Omnitrope. The approval itself is precedent setting, but the bigger ramifications are political: the action steps up the pressure on Congress to address the issue head-on.

Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel

The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel